Thomas C. Hamilton

High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis.

Andrew K. Godwin, A Meister, P J O'Dwyer et al. · Proceedings of the National Academy of Sciences · 1992 · 924 citations · Full text

Marked Increase, Oncogenic Agent, Medicine +14

AKT2, a putative oncogene encoding a member of a subfamily of protein-serine/threonine kinases, is amplified in human ovarian carcinomas.

J Q Cheng, Andrew K. Godwin, Alfonso Bellacosa et al. · Proceedings of the National Academy of Sciences · 1992 · 737 citations · Full text

Entire Coding Region, Amplified Sequences, Protein-serine/threonine Kinases +15

Characterization of a human ovarian carcinoma cell line (NIH:OVCAR-3) with androgen and estrogen receptors.

Thomas C. Hamilton, Robert C. Young, Wilma M. McKoy et al. · PubMed · 1983 · 543 citations

Estrogen Receptors, Endocrine Oncology, Medicine +14

Augmentation of adriamycin, melphalan, and cisplatin cytotoxicity in drug-resistant and -sensitive human ovarian carcinoma cell lines by buthionine sulfoximine mediated glutathione depletion

Thomas C. Hamilton, Margaret A. Winker, Karen G. Louie et al. · Biochemical Pharmacology · 1985 · 541 citations

Medicine, Cisplatin Cytotoxicity, Pharmacology +8

Characterization of a cis-diamminedichloroplatinum(II)-resistant human ovarian cancer cell line and its use in evaluation of platinum analogues.

Brent C. Behrens, Thomas C. Hamilton, Hidetaka Masuda et al. · PubMed · 1987 · 500 citations

Chemoprevention Strategy, Oncogenic Agent, Medicine +12